Systemic radionuclide therapy of bone metastases with strontium-89.
Bone metastases can have a devastating effect on a patient's quality of life due to pain and pathologic fractures. Local external beam radiotherapy is very effective for patients with only a few involved areas. Systemic therapy consisting of chemotherapy and hormonal therapy is extremely useful until the patient becomes refractory to treatment. Systemic radionuclide therapy using Strontium-89 has been shown to be very valuable, specifically in patients with bone metastases from hormonally-resistant prostate cancer. Studies have shown a significant improvement in analgesic requirement, time to further radiotherapy, and a reduction in tumor markers with this treatment. The use of Strontium-89 in the treatment of other bone neoplasms and the use of other radionuclides, such as Rhenium-186 HEDP and Samarium-153 EDT-MP, are still investigational.
Porter
A T
AT
Department of Radiation Oncology, Wayne State University School of Medicine, Detroit, Michigan.
Davis
L P
LP
D001859:Bone Neoplasms / Q000532:radiotherapy* / Q000556:secondary*; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000473:pathology; D013326:Strontium Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*
D013326:Strontium Radioisotopes